After enduring years of toxic and ineffective chemotherapies, Finn Sawyer died of rhabdomyosarcoma a month before his fourth birthday.

Finn was never offered broad-spectrum molecular diagnostics that could have identified life-saving modern treatments.

This is the fate of hundreds of thousands of Americans each year.

Finn Sawyer Access to Cancer Testing (A.C.T.)

Leads: Rep. Matsui (D-CA) and Rep. Bilirakis (R-FL) • Sen. Klobuchar (D-MN) and Sen. Wicker (R-MS)

The Finn Sawyer ACT will provide CMS (Medicare, Medicaid and CHIP) coverage for cancer patients to receive broad-spectrum molecular diagnostics at the time of their cancer diagnosis.

Broad-spectrum diagnostics look at all of the changes in a tumor compared to healthy tissue, rather than a small subset of changes. These changes can point to modern targeted therapies that may be effective for each patient.

Currently, CMS provides coverage of molecular diagnostics only at the time of cancer recurrence or metastasis. This approach denies patients and their doctors valuable and actionable information about a tumor’s causes, and the drugs that can help treat it.

The bill will also enhance educational and awareness initiatives on genomic testing and the vital role of genetic counseling.

Molecular diagnostics are cost effective, scientifically accepted, and widely available.

H.R. 5377, the version of this bill introduced into the 117th congress, was supported by more than 40 patient and clinician organizations.

“Every single patient who has cancer, at any age, should have molecular diagnostics available at the time of their initial diagnosis. We finally have the technology to really fine-tune cancer diagnosis and treatment by identifying what an individual’s own tumor will respond to, and administer treatment specific to their tumor. Not only will this improve their chance at cure, but also avoid throwing a handful of chemotherapy drugs at every patient, most of them coming with devastating side effects and causing long-term issues to those lucky enough to survive. We simply cannot keep giving broad, outdated treatment regimens to every patient. Our cure rates are not adequate if we are still losing babies, kids and adults to cancer. We must do better for our patients – ALL patients – so this testing must be available to everyone.”

– Dr. Candace Granberg, Mayo Clinic

To co-sponsor this legislation, please contact:
House: Chris Jones (Rep. Bilirakis): chris.jones@mail.house.gov
Senate: Ruth McDonald (Sen. Klobuchar): Ruth_McDonald@klobuchar.senate.gov
or Sally Farrington (Sen. Wicker): Sally_Thompson@Wicker.Senate.gov

To sign the petition: http://www.shepherd.bio/finn-sawyer-act